166 related articles for article (PubMed ID: 21039869)
21. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs.
Lorenzutti AM; MartÃn-Flores M; Litterio NJ; Himelfarb MA; Invaldi SH; Zarazaga MP
Can Vet J; 2017 Jan; 58(1):35-38. PubMed ID: 28042152
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
Burke JE; Hess RS; Silverstein DC
J Am Vet Med Assoc; 2021 Dec; 260(S1):S40-S45. PubMed ID: 34914630
[TBL] [Abstract][Full Text] [Related]
23. Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone.
Johnson RA
Vet Anaesth Analg; 2014 Jul; 41(4):406-10. PubMed ID: 24330310
[TBL] [Abstract][Full Text] [Related]
24. Effects of maropitant in cats receiving dexmedetomidine and morphine.
Martin-Flores M; Sakai DM; Learn MM; Mastrocco A; Campoy L; Boesch JM; Gleed RD
J Am Vet Med Assoc; 2016 Jun; 248(11):1257-61. PubMed ID: 27172341
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
26. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients.
Vail DM; Rodabaugh HS; Conder GA; Boucher JF; Mathur S
Vet Comp Oncol; 2007 Mar; 5(1):38-46. PubMed ID: 19754800
[TBL] [Abstract][Full Text] [Related]
28. The use of maropitant to prevent vomiting induced by epidural administration of preservative free morphine through an epidural catheter in a dog.
Mathis A; Lee K; Alibhai HI
Vet Anaesth Analg; 2011 Sep; 38(5):516-7. PubMed ID: 21831059
[No Abstract] [Full Text] [Related]
29. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats.
Hickman MA; Cox SR; Mahabir S; Miskell C; Lin J; Bunger A; McCall RB
J Vet Pharmacol Ther; 2008 Jun; 31(3):220-9. PubMed ID: 18471143
[TBL] [Abstract][Full Text] [Related]
30. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
Ogilvie GK; Richardson RC; Curtis CR; Withrow SJ; Reynolds HA; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1584-7. PubMed ID: 2599942
[TBL] [Abstract][Full Text] [Related]
31. Clinical Applications of Substance P (Neurokinin-1 Receptor) Antagonist in Canine Medicine.
Sharun K; Jambagi K; Arya M; Aakanksha ; Chaithra SN; Patel PK; Dixit SK; Dhama K
Arch Razi Inst; 2021 Nov; 76(5):1175-1182. PubMed ID: 35355772
[TBL] [Abstract][Full Text] [Related]
32. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial.
Quimby JM; Brock WT; Moses K; Bolotin D; Patricelli K
J Feline Med Surg; 2015 Aug; 17(8):692-7. PubMed ID: 25336450
[TBL] [Abstract][Full Text] [Related]
33. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of oral maropitant as an antiemetic in cats receiving morphine and dexmedetomidine.
Martin-Flores M; Sakai DM; Mastrocco A; Learn MM; Campoy L; Kirch PJ; Boesch JM; Gleed RD
J Feline Med Surg; 2016 Nov; 18(11):921-924. PubMed ID: 26534944
[TBL] [Abstract][Full Text] [Related]
35. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Beck TM
Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
39. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs.
Moore AS; Rand WM; Berg J; L'Heureux DA; Dennis RA
J Am Vet Med Assoc; 1994 Aug; 205(3):441-3. PubMed ID: 7961070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
